 |
 |

Bromocriptine and CF 25-397 in the Treatment of Tardive Dyskinesia
Carol A. Tamminga, MD;
Thomas N. Chase, MD
Arch Neurol. 1980;37(4):204-205.
Abstract
Dopamine agonist therapy using se lected drugs at particular dosage levels has been found to have therapeutic benefit in certain dyskinetic syndromes. Two ergot derivatives with dopamine agonist properties were administered at relatively low doses to eight neuroleptic-free schizophrenic patients with tardive dyskinesia. Neither agent significantly improved dyskinetic symptoms; no symptoms worsened. Dopamine agonists likely vary in their selective activation of functionally distinct dopamine receptors.
Author Affiliations
From the Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD.
Footnotes
Accepted for publication April 20, 1979.
Reprint requests to Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20205 (Dr Tamminga).
CiteULike Connotea Del.icio.us Digg Reddit Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Treatment of Tardive Dyskinesia With Bromocriptine: A Test of the Receptor Modification Strategy
Lieberman et al.
Arch Gen Psychiatry 1989;46:908-913.
ABSTRACT
Drugs Five Years Later: Bromocriptine
VANCE et al.
ANN INTERN MED 1984;100:78-91.
ABSTRACT
Is Bromocriptine a Dopamine Antagonist Treatment?
Lieberman et al.
Arch Gen Psychiatry 1983;40:469-470.
ABSTRACT
Is Bromocriptine a Dopamine Antagonist Treatment?-Reply
Jeste and Wyatt
Arch Gen Psychiatry 1983;40:470-470.
ABSTRACT
Therapeutic Strategies Against Tardive Dyskinesia: Two Decades of Experience
Jeste and Jed Wyatt
Arch Gen Psychiatry 1982;39:803-816.
ABSTRACT
|